Preclinical and Clinical Efficacy of Olorinab, a Peripherally Restricted, Highly Selective Full Agonist of the Cannabinoid Type 2 Receptor for the Management of Visceral Pain in Inflammatory Bowel Disease

Bruce Yacyshyn  1     Stuart M. Brierley  2     Beatriz Lindstrom  3     John Adams  3     Stewart Turner  3     Brett A. English  4     Kathe Stauber     Peter D.R. Higgins    
1 University of Cincinnati,Cincinnati,United States
2 Visceral Pain Research Group, Flinders University, SAHMRI,Adelaide,Australia
3 Arena Pharmaceuticals, Inc,San Diego,United States
4 Arena Pharmaceuticals, Inc,San Diego,United States;

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing